Titre : Fibrose

Fibrose : Questions médicales fréquentes

Termes MeSH sélectionnés :

Liver Function Tests
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Fibrose : Questions médicales les plus fréquentes", "headline": "Fibrose : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Fibrose : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-06", "dateModified": "2025-04-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Fibrose" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Processus pathologiques", "url": "https://questionsmedicales.fr/mesh/D010335", "about": { "@type": "MedicalCondition", "name": "Processus pathologiques", "code": { "@type": "MedicalCode", "code": "D010335", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Cicatrice hypertrophique", "alternateName": "Cicatrix, Hypertrophic", "url": "https://questionsmedicales.fr/mesh/D017439", "about": { "@type": "MedicalCondition", "name": "Cicatrice hypertrophique", "code": { "@type": "MedicalCode", "code": "D017439", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.355.274.505" } } }, { "@type": "MedicalWebPage", "name": "Chéloïde", "alternateName": "Keloid", "url": "https://questionsmedicales.fr/mesh/D007627", "about": { "@type": "MedicalCondition", "name": "Chéloïde", "code": { "@type": "MedicalCode", "code": "D007627", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.355.274.510" } } }, { "@type": "MedicalWebPage", "name": "Adhérences tissulaires", "alternateName": "Tissue Adhesions", "url": "https://questionsmedicales.fr/mesh/D000267", "about": { "@type": "MedicalCondition", "name": "Adhérences tissulaires", "code": { "@type": "MedicalCode", "code": "D000267", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.355.274.840" } } }, { "@type": "MedicalWebPage", "name": "Cirrhose du foie", "alternateName": "Liver Cirrhosis", "url": "https://questionsmedicales.fr/mesh/D008103", "about": { "@type": "MedicalCondition", "name": "Cirrhose du foie", "code": { "@type": "MedicalCode", "code": "D008103", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.355.412" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Cirrhose biliaire", "alternateName": "Liver Cirrhosis, Biliary", "url": "https://questionsmedicales.fr/mesh/D008105", "about": { "@type": "MedicalCondition", "name": "Cirrhose biliaire", "code": { "@type": "MedicalCode", "code": "D008105", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.355.412.400" } } } ] }, { "@type": "MedicalWebPage", "name": "Fibrose systémique néphrogénique", "alternateName": "Nephrogenic Fibrosing Dermopathy", "url": "https://questionsmedicales.fr/mesh/D054989", "about": { "@type": "MedicalCondition", "name": "Fibrose systémique néphrogénique", "code": { "@type": "MedicalCode", "code": "D054989", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.355.550" } } }, { "@type": "MedicalWebPage", "name": "Fibrose péritonéale", "alternateName": "Peritoneal Fibrosis", "url": "https://questionsmedicales.fr/mesh/D056627", "about": { "@type": "MedicalCondition", "name": "Fibrose péritonéale", "code": { "@type": "MedicalCode", "code": "D056627", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.355.625" } } }, { "@type": "MedicalWebPage", "name": "Fibrose pulmonaire", "alternateName": "Pulmonary Fibrosis", "url": "https://questionsmedicales.fr/mesh/D011658", "about": { "@type": "MedicalCondition", "name": "Fibrose pulmonaire", "code": { "@type": "MedicalCode", "code": "D011658", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.355.644" } } }, { "@type": "MedicalWebPage", "name": "Fibrose rétropéritonéale", "alternateName": "Retroperitoneal Fibrosis", "url": "https://questionsmedicales.fr/mesh/D012185", "about": { "@type": "MedicalCondition", "name": "Fibrose rétropéritonéale", "code": { "@type": "MedicalCode", "code": "D012185", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.355.700" } } } ], "about": { "@type": "MedicalCondition", "name": "Fibrose", "alternateName": "Fibrosis", "code": { "@type": "MedicalCode", "code": "D005355", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Nikolaos G Frangogiannis", "url": "https://questionsmedicales.fr/author/Nikolaos%20G%20Frangogiannis", "affiliation": { "@type": "Organization", "name": "The Wilf Family Cardiovascular Research Institute, Department of Medicine (Cardiology), Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: nikolaos.frangogiannis@einsteinmed.org." } }, { "@type": "Person", "name": "Pierre-Régis Burgel", "url": "https://questionsmedicales.fr/author/Pierre-R%C3%A9gis%20Burgel", "affiliation": { "@type": "Organization", "name": "Université Paris Cité and Institut Cochin, Inserm U1016, Paris, France." } }, { "@type": "Person", "name": "Jane C Davies", "url": "https://questionsmedicales.fr/author/Jane%20C%20Davies", "affiliation": { "@type": "Organization", "name": "National Heart & Lung Institute, Imperial College London, London, UK." } }, { "@type": "Person", "name": "Na Liu", "url": "https://questionsmedicales.fr/author/Na%20Liu", "affiliation": { "@type": "Organization", "name": "Department of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Nanjing, Jiangsu, China." } }, { "@type": "Person", "name": "Ruoshui Li", "url": "https://questionsmedicales.fr/author/Ruoshui%20Li", "affiliation": { "@type": "Organization", "name": "The Wilf Family Cardiovascular Research Institute, Department of Medicine (Cardiology), Albert Einstein College of Medicine, Bronx, NY, United States of America." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Liver resection versus microwave ablation for solitary and small (≤ 3 cm) HCC with early recurrence in different stages of liver cirrhosis: A propensity score matching study.", "datePublished": "2024-02-10", "url": "https://questionsmedicales.fr/article/38342723", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.asjsur.2024.01.184" } }, { "@type": "ScholarlyArticle", "name": "Burden of liver complications related to non-alcoholic fatty liver disease in China from 2005 to 2019: Observations from the Global Burden of Disease Study, 2019.", "datePublished": "2023-03-07", "url": "https://questionsmedicales.fr/article/36781698", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/dom.15010" } }, { "@type": "ScholarlyArticle", "name": "Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study.", "datePublished": "2023-02-02", "url": "https://questionsmedicales.fr/article/36727522", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1161/ATVBAHA.122.318661" } }, { "@type": "ScholarlyArticle", "name": "Editorial: The Metabolic (Dysfunction) Associated Fatty Liver Disease (MAFLD)-Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: A Forced Consensus and The Risk of a World Divide.", "datePublished": "2022-08-15", "url": "https://questionsmedicales.fr/article/36017581", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.12659/MSM.938080" } }, { "@type": "ScholarlyArticle", "name": "BRUCE liver-deficiency potentiates MASLD/MASH in PTEN liver-deficient background by impairment of mitochondrial metabolism in hepatocytes and activation of STAT3 signaling in hepatic stellate cells.", "datePublished": "2024-09-14", "url": "https://questionsmedicales.fr/article/39314445", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1101/2024.09.13.611500" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "États, signes et symptômes pathologiques", "item": "https://questionsmedicales.fr/mesh/D013568" }, { "@type": "ListItem", "position": 3, "name": "Processus pathologiques", "item": "https://questionsmedicales.fr/mesh/D010335" }, { "@type": "ListItem", "position": 4, "name": "Fibrose", "item": "https://questionsmedicales.fr/mesh/D005355" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Fibrose - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Fibrose", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-03", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Fibrose", "description": "Comment diagnostique-t-on la fibrose pulmonaire ?\nQuels tests sanguins sont utiles pour la fibrose ?\nLa fibrose peut-elle être détectée par échographie ?\nQuels sont les signes radiologiques de la fibrose ?\nLa fibrose peut-elle être confondue avec d'autres maladies ?", "url": "https://questionsmedicales.fr/mesh/D005355?mesh_terms=Liver+Function+Tests&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Fibrose", "description": "Quels sont les symptômes de la fibrose pulmonaire ?\nLa fibrose hépatique provoque-t-elle des douleurs ?\nQuels signes indiquent une fibrose cardiaque ?\nLa fibrose peut-elle entraîner une perte de poids ?\nQuels symptômes sont associés à la fibrose systémique ?", "url": "https://questionsmedicales.fr/mesh/D005355?mesh_terms=Liver+Function+Tests&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Fibrose", "description": "Comment prévenir la fibrose pulmonaire ?\nPeut-on prévenir la fibrose hépatique ?\nLes examens réguliers aident-ils à prévenir la fibrose ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLe contrôle des maladies chroniques aide-t-il ?", "url": "https://questionsmedicales.fr/mesh/D005355?mesh_terms=Liver+Function+Tests&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Fibrose", "description": "Quels traitements existent pour la fibrose pulmonaire ?\nLa chirurgie est-elle une option pour la fibrose ?\nQuels médicaments sont utilisés pour la fibrose hépatique ?\nLa physiothérapie aide-t-elle en cas de fibrose ?\nY a-t-il des traitements naturels pour la fibrose ?", "url": "https://questionsmedicales.fr/mesh/D005355?mesh_terms=Liver+Function+Tests&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Fibrose", "description": "Quelles sont les complications de la fibrose pulmonaire ?\nLa fibrose hépatique peut-elle entraîner une cirrhose ?\nQuels risques sont associés à la fibrose cardiaque ?\nLa fibrose peut-elle affecter la qualité de vie ?\nY a-t-il des complications psychologiques liées à la fibrose ?", "url": "https://questionsmedicales.fr/mesh/D005355?mesh_terms=Liver+Function+Tests&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Fibrose", "description": "Quels sont les facteurs de risque de la fibrose pulmonaire ?\nL'âge est-il un facteur de risque pour la fibrose ?\nLes maladies auto-immunes augmentent-elles le risque de fibrose ?\nLe diabète est-il un facteur de risque pour la fibrose hépatique ?\nL'exposition professionnelle influence-t-elle le risque de fibrose ?", "url": "https://questionsmedicales.fr/mesh/D005355?mesh_terms=Liver+Function+Tests&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on la fibrose pulmonaire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des examens d'imagerie, des tests fonctionnels pulmonaires et parfois une biopsie." } }, { "@type": "Question", "name": "Quels tests sanguins sont utiles pour la fibrose ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests pour évaluer les marqueurs inflammatoires et la fonction hépatique peuvent être effectués." } }, { "@type": "Question", "name": "La fibrose peut-elle être détectée par échographie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'échographie peut aider à visualiser la fibrose dans certains organes comme le foie." } }, { "@type": "Question", "name": "Quels sont les signes radiologiques de la fibrose ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des opacités, des réticulations et des anomalies de la structure tissulaire." } }, { "@type": "Question", "name": "La fibrose peut-elle être confondue avec d'autres maladies ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être confondue avec des maladies comme la pneumonie ou la cirrhose." } }, { "@type": "Question", "name": "Quels sont les symptômes de la fibrose pulmonaire ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent une toux persistante, un essoufflement et une fatigue chronique." } }, { "@type": "Question", "name": "La fibrose hépatique provoque-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut causer des douleurs abdominales et une sensation de lourdeur dans l'abdomen." } }, { "@type": "Question", "name": "Quels signes indiquent une fibrose cardiaque ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des palpitations, un essoufflement à l'effort et des œdèmes." } }, { "@type": "Question", "name": "La fibrose peut-elle entraîner une perte de poids ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la fibrose peut causer une perte de poids due à une mauvaise absorption des nutriments." } }, { "@type": "Question", "name": "Quels symptômes sont associés à la fibrose systémique ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs articulaires, une raideur cutanée et des troubles circulatoires." } }, { "@type": "Question", "name": "Comment prévenir la fibrose pulmonaire ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le tabagisme, réduire l'exposition à des polluants et traiter les infections respiratoires." } }, { "@type": "Question", "name": "Peut-on prévenir la fibrose hépatique ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en adoptant un mode de vie sain, en évitant l'alcool et en se vaccinant contre l'hépatite." } }, { "@type": "Question", "name": "Les examens réguliers aident-ils à prévenir la fibrose ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des examens réguliers peuvent détecter précocement des maladies pouvant mener à la fibrose." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée riche en antioxydants peut aider à prévenir la fibrose." } }, { "@type": "Question", "name": "Le contrôle des maladies chroniques aide-t-il ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, bien gérer des maladies comme le diabète ou l'hypertension peut réduire le risque de fibrose." } }, { "@type": "Question", "name": "Quels traitements existent pour la fibrose pulmonaire ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des médicaments antifibrotiques, la réhabilitation pulmonaire et l'oxygénothérapie." } }, { "@type": "Question", "name": "La chirurgie est-elle une option pour la fibrose ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, dans certains cas avancés, une transplantation d'organe peut être envisagée." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés pour la fibrose hépatique ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments pour traiter la cause sous-jacente, comme les antiviraux pour l'hépatite, sont utilisés." } }, { "@type": "Question", "name": "La physiothérapie aide-t-elle en cas de fibrose ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la physiothérapie peut améliorer la fonction pulmonaire et la qualité de vie." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour la fibrose ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Certaines approches comme les antioxydants peuvent aider, mais il faut consulter un médecin." } }, { "@type": "Question", "name": "Quelles sont les complications de la fibrose pulmonaire ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'insuffisance respiratoire, les infections pulmonaires et les embolies." } }, { "@type": "Question", "name": "La fibrose hépatique peut-elle entraîner une cirrhose ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la fibrose hépatique peut évoluer vers une cirrhose, entraînant des complications graves." } }, { "@type": "Question", "name": "Quels risques sont associés à la fibrose cardiaque ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent l'insuffisance cardiaque, les arythmies et les accidents vasculaires cérébraux." } }, { "@type": "Question", "name": "La fibrose peut-elle affecter la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut réduire la qualité de vie en limitant les activités quotidiennes et en causant de la douleur." } }, { "@type": "Question", "name": "Y a-t-il des complications psychologiques liées à la fibrose ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent éprouver de l'anxiété et de la dépression en raison de leur état de santé." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de la fibrose pulmonaire ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent le tabagisme, l'exposition à des substances toxiques et des infections antérieures." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour la fibrose ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de fibrose augmente avec l'âge, surtout après 50 ans." } }, { "@type": "Question", "name": "Les maladies auto-immunes augmentent-elles le risque de fibrose ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme la sclérodermie peuvent prédisposer à la fibrose dans divers organes." } }, { "@type": "Question", "name": "Le diabète est-il un facteur de risque pour la fibrose hépatique ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut augmenter le risque de fibrose hépatique en raison de la stéatose." } }, { "@type": "Question", "name": "L'exposition professionnelle influence-t-elle le risque de fibrose ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des professions exposant à des poussières ou des produits chimiques peuvent augmenter le risque." } } ] } ] }

Sources (10000 au total)

Liver resection versus microwave ablation for solitary and small (≤ 3 cm) HCC with early recurrence in different stages of liver cirrhosis: A propensity score matching study.

This study aimed to compare the effectiveness of liver resection (LR) and microwave ablation (MWA) in hepatocellular carcinoma (HCC) patients with early recurrence and varying stages of cirrhosis.... This study analyzed patients with HCC who underwent hepatectomy and experienced early tumor recurrence (≤3 cm) between December 2002 and December 2020 at the Tongji Hospital. Treatment effectiveness w... This study included 295 patients (106, LR; 189, MWA), 86 patients in each of the 2 groups were chosen for further comparison, after PSM. After PSM, both LR and MWA demonstrated similar recurrence-free... LR is more effective than MWA for early recurrence of HCC in patients without cirrhosis or with mild cirrhosis, showing improved RFS and OS rates. In patients with moderate or severe cirrhosis, the OS...

Burden of liver complications related to non-alcoholic fatty liver disease in China from 2005 to 2019: Observations from the Global Burden of Disease Study, 2019.

To assess the burden of liver complications related to non-alcoholic fatty liver disease (LC-NAFLD) from 2005 to 2019 in China.... We used data from the Global Burden of Disease, Injuries, and Risk Factors Study, 2019, to present contemporary and varying profiles of China's LC-NAFLD burden. The Joinpoint Regression model and Gaus... In 2019, China had 293.42 million (95% uncertainty interval [UI]: 263.69-328.44) LC-NAFLD cases with a prevalence rate and DALYs of 20.63 (95% UI: 23.09-18.54) per 1000 people and 591.03 thousand (95%... The LC-NAFLD burden in China is substantial and has increased markedly over the past 15 years. Effective measures for low SDI regions and men are needed to address the rapidly increasing NAFLD burden....

Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study.

In cross-sectional and retrospective cohort studies, we examined comparative associations between nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAF... Participants who had health examinations between 2010 and 2019 were analyzed. Liver ultrasonography and coronary artery computed tomography were used to diagnose fatty liver and CAC. Participants were... In cross-sectional analyses, 162 180 participants were included. Compared with either the no-NAFLD or no-MAFLD groups, the NAFLD and MAFLD groups were associated with a higher risk of prevalent CAC (N...

Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on major liver outcomes in metabolic dysfunction-associated steatotic liver disease.

To compare the effectiveness of sodium-glucose co-transporter-2 inhibitors (SGLT2is) with dipeptidyl peptidase-4 inhibitors (DPP4is) on major liver outcomes (MLO) in patients with type 2 diabetes (T2D... We included adult patients with T2D and MASLD, using metformin without specific liver conditions or surgeries, from the Merative MarketScan database. Patients initiating SGLT2is or DPP4is from 1 Janua... Among 44 651 patients, 22 100 initiated SGLT2is, and 22 551 began DPP4is. After weighting, the incidence rate of MLO in the SGLT2i group was 3.8 per 1000 person-years, and it was 3.9 per 1000 person-y... In patients with T2D and MASLD, SGLT2is did not show a lower risk of MLO compared with DPP4is. Clinicians should consider the overall patient conditions and the additional benefits of SGLT2is to suppo...

Comparisons of Percutaneous Ablation, Open or Laparoscopic Liver Resection for Barcelona Clinic Liver Cancer Stage 0-A Hepatocellular Carcinoma: A Concurrent Generalized Propensity Score Analysis.

Liver resection and ablation remain the most common therapeutic options for Barcelona Clinic Liver Cancer (BCLC) stage 0-A hepatocellular carcinoma (HCC), but there is a lack of evidence to show which... This was a retrospective observational cohort study. A series of generalized propensity score methods for multiple treatment groups were performed to concurrently compare the clinical outcomes of thes... Of the 1778 patients included, 1237, 307 and 234 underwent OLR, LLR and PA, respectively. After overlap weighting, which was the optimal adjustment strategy, patients in the minimally invasive group (... In the observational study using various covariate adjustment analysis with excellent balance, LLR is not only minimally invasive, but also provides better RFS and equivalent OS for patients with BCLC...

Oleuropein mitigates non-alcoholic fatty liver disease (NAFLD) and modulates liver metabolites in high-fat diet-induced obese mice via activating PPARα.

This study aimed to elucidate the mechanism of oleuropein (OLE) ameliorates non-alcoholic fatty liver disease (NAFLD) and its underlying mechanisms.... Male C57BL/6J mice were fed either a low-fat diet (LFD), a high-fat diet (HFD), or a HFD supplemented with 0.03% (w/w) OLE for 16 weeks. OLE supplementation decreased body weight and liver weight, imp... Our results suggest that OLE alleviates NAFLD in mice by activating PPARα and modulating liver metabolites. © 2024 Society of Chemical Industry....

The correlation between liver fibrosis and the 10-year estimated risk of cardiovascular disease in adults with metabolic-associated fatty liver disease: A cross-sectional study in Vietnam.

Metabolic-associated fatty liver disease (MAFLD) emerged as a novel term replacing nonalcoholic fatty liver disease (NAFLD) in 2020. While most MAFLD patients are asymptomatic, long-term hepatic fat a... Between January 2022 and August 2023, this cross-sectional study enrolled 139 MAFLD patients. We employed the systematic coronary risk evaluation 2 (SCORE2) and the systematic coronary risk evaluation... Most MAFLD patients were categorized as having high or very high CV risk based on the SCORE2 and SCORE2-OP. Liver fibrosis, measured by the FIB-4 score, significantly differed among the various CV ris... Patients with MAFLD predominantly face high or very high CV risks, with elevated liver fibrosis associated with increased 10-year estimated CVD risk. The FIB-4 score exhibits promising predictive valu...